tabolism 2003;52:862–867.32. Okada S, Ishii K, Hamada H, Tanokuchi S, Ichiki K, Ota Z: The effect of an alpha-glucosidase inhibitor andinsulin on glucose metabolism and lipid profiles innon-insulin-dependent diabetes mellitus. J Int MedRes 1996;24:438–447. 33. Buysschaert M, Bobbioni E, Starkie M, Frith L: Trogli- tazone in combination with sulphonylurea improvesglycaemic control in Type 2 diabetic patients inade-quately controlled by sulphonylurea therapy alone.Troglitazone Study Group. Diabet Med 1999;16:147–153. 34. Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A: Comparison between repaglinide and glipizide inType 2 diabetes mellitus: A 1-year multicentre study.Diabet Med 2001;18:395–401. 35. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective inpatients with type 2 diabetes. J Clin Endocrinol Metab2001;86:280–288. 36. Phillips LS, Grunberger G, Miller E, Patwardhan R,